Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/02/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Introduction

Revised text to state that pathogenic variants are estimated to account for only 5% to 8% of renal cell cancer cases overall.

Revised text to state that the natural history of each hereditary kidney cancer syndrome is distinct and influenced by several factors, including histologic features and underlying genetic alterations.

Major Heritable Renal Cell Cancer Syndromes

Added text to state that autosomal dominant means that it is sufficient for the altered gene to be present in one of the parents and that the chances of transmitting this gene and the disease to the offspring is 50% for each pregnancy.

The Introduction, Genetics, and Molecular biology subsections for Von Hippel-Lindau syndrome (VHL) were comprehensively reviewed and revised.

Added text to state that a small, randomized clinical trial showed that intralesional injection of botulinum toxin A (Botox) may improve quality of life in patients with cutaneous lesions associated with hereditary leiomyomatosis and renal cell cancer (cited Naik et al. as reference 187).

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Major Heritable Renal Cell Cancer Syndromes

Next section >
About This PDQ Summary